Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Immunic Inc

IMUX
Current price
0.98 USD +0.038 USD (+3.98%)
Last closed 0.94 USD
ISIN US4525EP1011
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 93 901 152 USD
Yield for 12 month -20.33 %
1Y
3Y
5Y
10Y
15Y
IMUX
21.11.2021 - 28.11.2021

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York. Address: 1200 Avenue of the Americas, New York, NY, United States, 10036

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

13.12 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

-111 000 USD

Current Quarter

Last Quarter

Key Figures IMUX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -97 918 000 USD
Operating Margin TTM
Price to Earnings
Return On Assets TTM -128.79 %
PEG Ratio
Return On Equity TTM -424.44 %
Wall Street Target Price 13.12 USD
Revenue TTM
Book Value 0.20 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -1.00 USD
Diluted Eps TTM -1.00 USD
Most Recent Quarter IV 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics IMUX

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History IMUX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor 1:40
Payout Ratio
Last Split Date 15.04.2019

Stock Valuation IMUX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA 0.21
Price Book MRQ 5.10

Financials IMUX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators IMUX

For 52 weeks

0.83 USD 2.11 USD
50 Day MA 1.08 USD
Shares Short Prior Month 2 316 757
200 Day MA 1.24 USD
Short Ratio 3.25
Shares Short 2 022 033
Short Percent 2.26 %